Heart failure & cardiomyopathies
Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy with Heart Failure: Baseline Characteristics of the PARACHUTE-HF Trial
Authors' conclusion
Baseline characteristics of this study highlight the unique clinical profile of patients with CCC-related HFrEF, including the high proportion of women affected, lower rates of comorbidities (hypertension/diabetes) and higher prevalence of stroke and pacemaker implantation when compared with other non-CCC-related HFrEF studies.
Study context
- Population
- Heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy, New York Heart Association (NYHA) II–IV, left ventricular ejection fraction (LVEF) ≤40%
- Participants
- 922 participants
- Comparison
- Sacubitril/valsartan vs enalapril
- Primary endpoint
- Hierarchical composite of:
- CV death
- First HF hospitalization
- Change in NT-proBNP
Methodological detailsmulticentre, active-controlled, open-label
- Multicentre
- Active-controlled
- Open-label
Primary result
As reported in the abstract
Baseline characteristics
- Mean age
- 64.2 years
- Women
- 42.0%
- Baseline LVEF
- 29.8%
- NYHA class II
- 61.7%
- NYHA class III/IV
- 38.2%
- Hypertension
- 40.5%
- AF/flutter
- 32.5%
- Ventricular arrhythmia
- 24.7%
- Stroke
- 12.5%
- Conventional pacemaker, CRT or ICD
- 46.0%
- Mean SBP
- 118 mmHg
- Median NT-proBNP
- 1730 pg/ml
Original publication
Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy with Heart Failure: Baseline Characteristics of the PARACHUTE-HF Trial. Eur J Heart Fail. Published 8 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →